Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drastic action by Schultz aims to right Teva’s ship

Executive Summary

Teva president and chief executive Kåre Schultz is seeking to achieve cost savings of US$3 billion by the end of 2019, through significant cuts to the firm’s staff, facilities and product portfolio. David Wallace reports.

You may also be interested in...



Five Things Facing Teva’s New CEO Richard Francis

With Teva clearing up early who will replace outgoing president and CEO Kåre Schultz, Generics Bulletin looks at five issues that await his replacement, the former Sandoz head Richard Francis.

Largest PBMs Eliminate Consumers’ Cost Sharing For Opill On Most Commercial Plans

Decisions by “big three” PBMs suggest they’re taking proactive steps to comply with potential HRSA rulemaking to require most health plans, under Affordable Care Act regulations, to cover Opill and other types of OTC birth control without cost sharing.

First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations

With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB000164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel